DORAVIRINE, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE

313 reported adverse events

Drug classes: Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

These side effects are most commonly reported by patients taking DORAVIRINE, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE:

# Side effect Count
0 DEATH 20
1 NAUSEA 20
2 WEIGHT INCREASED 18
3 PAIN 17
4 ANXIETY 14
5 FATIGUE 13
6 NO ADVERSE EVENT 13
7 PATHOGEN RESISTANCE 13
8 DEPRESSION 12
9 HEADACHE 12
See all common reactions for DORAVIRINE, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE

DORAVIRINE, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 ADRENAL ANDROGEN EXCESS 5 0.6250
1 SUBCUTANEOUS FLUID COLLECTION 2 0.2000
2 CHOANAL STENOSIS 4 0.1667
3 OROPHARYNGEAL CANCER RECURRENT 1 0.1667
4 BLOOD HIV RNA BELOW ASSAY LIMIT 2 0.1333
5 CARDIOVASCULAR EXAMINATION ABNORMAL 1 0.1250
6 HEPATITIS B E ANTIBODY POSITIVE 1 0.0455
7 CSF HIV VIRUS IDENTIFIED 1 0.0435
8 LATENT SYPHILIS 1 0.0435
9 AMNIOTIC MEMBRANE GRAFT 1 0.0385
See all enriched reactions for DORAVIRINE, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE